Top Stories
No new vouchers have been awarded since May, according to a Reuters report, raising questions about the future of the drug review initiative.
The Chinese firm is developing radiopharmaceutical assets targeting oncology and neurological disorders, several of which are lined up for IND submissions.
The spin-off from Addex Therapeutics is developing NTX-253, an oral muscarinic M4 positive allosteric modulator, for schizophrenia.
Pfizer retains full ownership of berobenatide, as well as operational control and decision-making over its development, while Blackstone is eligible for milestone-based payments.
The Dutch biotech's lead programme is VTx-002, a first-in-class vectorised antibody targeting TDP-43 pathology in people with amyotrophic lateral sclerosis (ALS).
Conference News
Foundayo could be headed for an OSA indication, but will physicians favour its oral convenience over Zepbound’s stronger efficacy?
According to Fidelity, RBC Capital Markets said Legend Biotech’s Carvykti is positioned to sustain growth into 2027, potentially supporting profitability and margin expansion.Indicated for multiple my...
SHANGHAI and HONG KONG, Nov. 11, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) , a leading innovative, commercial-stage global biotech company dedicated to discoveri...
SHANGHAI, Nov. 11, 2026 /PRNewswire/ -- Laekna (2105.HK) announced that LAE124, its internally discovered novel oral small-molecule dual Amylin/Calcitonin receptor agonist (DACRA) for the treatment of...
FirstWord will be speaking with a leading expert about detailed Phase II data for Beeline's afimetoran, and what they suggest about the prospects for TLR7/8 inhibitors in lupus.
